CD80


Also found in: Wikipedia.

CD80

a type I transmembrane protein on activated B cells, activated monocytes, activated follicular dendritic cells, and some activated T cells; provides a costimulatory signal to T cells during antigen presentation; expressed in B lymphoblastoid cells.
References in periodicals archive ?
For instance, AstraZeneca's Durvalumab (Imfinzi) was approved in 2017, as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb received approval for Nivolumab (Opdivo) in adjuvant treatment of melanoma.
Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor's immune-evading tactics and releasing the inhibition of immune responses.
In our previous study, we reconstructed an associative network for TB and revealed novel candidate genes including CD4, CD69, CD79, CD80, MUC16, HCST, ADA, CP, SPP1, CXCR4, AGER, and PACRG.
This included in vitro binding studies, showing high-affinity binding to CTLA-4 and inhibition of binding of its ligands CD80 and CD86 to human CTLA4.
CD28 and CTLA-4 share similar ligands called CD80 (B7.1) and CD86 (B7.2).
Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-KB-dependent pathway.
Imfinzi is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80. Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab have failed to achieve the primary endpoints of improving overall survival compared to standard-of-care chemotherapy in the primary analysis population of patients.
By analyzing patient samples, cell lines and mouse lymphoma models the following was observed:Murine and human B-lymphoma cell lines express TLR4 and respond in vitro to G100 stimulation with upregulation of MHC-II and co-stimulatory markers CD40 and CD80, typical of the activation of antigen-presenting function of B-cells; In vivo murine tumors of lymphoma models respond to treatment with G100 in injected tumors as well as distal, untreated tumors showing local and abscopal tumor control, mediated by systemic T-cell response; Approximately 70% of follicular lymphoma patients in a Phase 1/2 study express TLR4 in greater than50% of tumor cells in baseline biopsies.
The cytotoxic T lymphocyte-associated molecule-4 (CTLA-4, also termed CD152)on activated T cells connects to CD86 and CD80, and some of its inhibitory effects may be modulated by SH2-containing phosphatase (3, 4).
In this feasibility study, we repurposed mouse PET data gathered with our PET tracers under development [[sup.11]C]AM7 and [[sup.11]C]MT107, both targeting the human costimulatory molecule CD80 (hCD80) [16] (Taddio et al., in preparation; Figure 1).